Da zonisamid og dets metabolitter udskilles renalt, bør det seponeres hos patienter, som udvikler akut nyreinsufficiens eller hvor der observeres en klinisk betydningsfuld vedvarende stigning i serumcreatinin.
Since zonisamide and its metabolites are excreted renally, it should be discontinued in patients who develop acute renal failure or where a clinically significant sustained increase in serum creatinine is observed.